topic

569 Dissecting resistance to immune checkpoint blockade in bladder cancer: single cell analyses link pro-inflammatory macrophages and IL-6 to CD8⁺ T cell suppression
Michelle A Tran, Adam M Farkas, Dina Youssef, Kristin Beaumont, Seunghee Kim-Schulze, Amir Horowitz, John Sfakianos, Matthew Galsky, Nina Bhardwaj

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A646; DOI: 10.1136/jitc-2023-SITC2023.0569
570 Successful immune-checkpoint therapy promotes spatial reorganization of the lymphoid and myeloid cellular populations
Ruan Vieira Medrano, Vladimir Sukhov, Bassem Ben Cheikh, Patrick Leinert, Wm Pat Leinert, Max Artyomov, Robert Schreiber

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A647; DOI: 10.1136/jitc-2023-SITC2023.0570
571 Exploring anti-PD-1 resistance mechanisms for therapeutic targeting in non-small cell lung cancer
Haoyi Wu, Jessica M Konen, B Leticia Rodriguez, Yanhua Tian, Jared Fradette, Don Gibbons

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A648; DOI: 10.1136/jitc-2023-SITC2023.0571
572 PYX-102, an anti-KLRG1 antibody, enhances cytotoxic activity of CD8-T-cells from PBMC and human tumor samples by blocking the interaction between KLRG1 and cadherins
Kei Yasuda, Liyang Diao, Jianwen Feng, Matthew Iovino, Sara Lewandowski, Anthony Rodriguez, Philipp Steiner, Dan Felitsky, Ronald Herbst, Ben Keller, Ona Miller, Alyssa Quigley, Jan Pinkas

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A649; DOI: 10.1136/jitc-2023-SITC2023.0572
573 BTN1A1-Targeted Immunotherapy Combined with Standard Therapy in Small Cell Lung Cancer (SCLC) and Colorectal Cancer
Stephen S Yoo, Soohyeon Lee, Seung-Hoon Lee, Young Seung Kim, Chunai Wu, Andrew H Park

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A650; DOI: 10.1136/jitc-2023-SITC2023.0573
575 Preclinical characterization of LAE111, a potent anti-LILRB1/LILRB2 antagonist bispecific antibody
Minhua Zhang, Rong Wu, Chaojun Cai, Xiang-Ju Justin Gu

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A651; DOI: 10.1136/jitc-2023-SITC2023.0575
576 Blocking FGFR2 and SHP2 can effectively suppress tumor progression in gastric cancers with FGFR2 alteration
Yue Zhang, Yue Wang, Hanbing Wang, Lixia Yu, Baorui Liu, Jia Wei

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A652; DOI: 10.1136/jitc-2023-SITC2023.0576
577 Cancer immunotherapy responses persist after lymph node resection
Hengbo Zhou, Meghan J O’Melia, James W Baish, Laurel B Darragh, Pinji Lei, Lutz Menzel, Johanna J Rajotte, Mohammad R Nikmaneshi, Mohammad S Razavi Rizi, Matthew G Vander Heiden, Lance L Munn, Sana D Karam, Timothy P Padera

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A653-A656; DOI: 10.1136/jitc-2023-SITC2023.0577
578 Anti-PD-1 therapy alters the generation and durability of de novo responses to vaccination in humans
Kelly P Burke, Taras M Chicz, Joanna Baginska, Julia Huezo, Marta Holovatska, Michael Manos, Duck Kyun Yoo, Fnu Keerti, Caihong Bi, Ryan McNamara, Duane Wesemann, F Stephen Hodi, Elizabeth I Buchbinder, Arlene Sharpe

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A657; DOI: 10.1136/jitc-2023-SITC2023.0578
579 Evaluation of cemiplimab treatment duration: clinical outcomes in advanced CSCC
Domenico Mallardo, Francesca Sparano, Maria Grazia Vitale, Claudia Trojaniello, Eleonora Cioli, Assunta Esposito, Lucia Festino, Mario Mallardo, Vito Vanella, Teresa De Cristofaro, Boanca Arianna Facchini, Paolo Meinardi, Margaret Ottaviano, Corrado Caraco, Alfredo Budillon, Ester Simeone, Paolo Ascierto

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A658-A659; DOI: 10.1136/jitc-2023-SITC2023.0579

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages